$0.18 EPS Expected for OptimizeRx Co. (NASDAQ:OPRX) This Quarter

Wall Street brokerages expect OptimizeRx Co. (NASDAQ:OPRX) to post earnings per share (EPS) of $0.18 for the current fiscal quarter, according to Zacks. Three analysts have made estimates for OptimizeRx’s earnings, with the highest EPS estimate coming in at $0.19 and the lowest estimate coming in at $0.18. OptimizeRx posted earnings per share of $0.16 during the same quarter last year, which would indicate a positive year-over-year growth rate of 12.5%. The company is scheduled to announce its next quarterly earnings results on Wednesday, February 23rd.

According to Zacks, analysts expect that OptimizeRx will report full-year earnings of $0.40 per share for the current financial year, with EPS estimates ranging from $0.40 to $0.41. For the next financial year, analysts expect that the company will post earnings of $0.74 per share, with EPS estimates ranging from $0.63 to $0.80. Zacks’ EPS calculations are a mean average based on a survey of analysts that follow OptimizeRx.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Tuesday, November 9th. The company reported $0.09 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.04). The business had revenue of $16.13 million during the quarter, compared to the consensus estimate of $14.82 million. OptimizeRx had a return on equity of 2.03% and a net margin of 4.16%. During the same quarter in the previous year, the firm posted ($0.01) earnings per share.

Several equities analysts recently commented on OPRX shares. Roth Capital upped their price objective on OptimizeRx from $85.00 to $112.00 and gave the company a “buy” rating in a research note on Wednesday, November 10th. Zacks Investment Research cut OptimizeRx from a “hold” rating to a “strong sell” rating in a research report on Friday, November 19th. B. Riley restated a “buy” rating and set a $102.00 price objective on shares of OptimizeRx in a research report on Monday, October 18th. TheStreet lowered OptimizeRx from a “b-” rating to a “c” rating in a research note on Monday, December 27th. Finally, William Blair restated an “outperform” rating on shares of OptimizeRx in a report on Tuesday, November 9th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat, OptimizeRx presently has an average rating of “Buy” and a consensus price target of $84.60.

NASDAQ:OPRX traded down $1.76 during trading hours on Friday, hitting $49.68. 334,790 shares of the company traded hands, compared to its average volume of 250,019. OptimizeRx has a one year low of $38.74 and a one year high of $99.18. The firm’s 50-day simple moving average is $64.76 and its 200-day simple moving average is $68.11. The company has a market cap of $882.81 million, a PE ratio of 354.57 and a beta of 0.55.

In related news, insider Stephen L. Silvestro sold 13,241 shares of the firm’s stock in a transaction on Friday, December 17th. The shares were sold at an average price of $54.87, for a total transaction of $726,533.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Miriam J. Paramore sold 3,558 shares of OptimizeRx stock in a transaction that occurred on Thursday, December 2nd. The shares were sold at an average price of $61.48, for a total transaction of $218,745.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 97,865 shares of company stock valued at $7,293,401. Corporate insiders own 6.50% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in OPRX. Louisiana State Employees Retirement System acquired a new stake in OptimizeRx in the fourth quarter valued at approximately $534,000. State of Alaska Department of Revenue acquired a new position in OptimizeRx in the 4th quarter valued at about $781,000. UBS Asset Management Americas Inc. increased its stake in OptimizeRx by 2.4% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 10,035 shares of the company’s stock valued at $858,000 after buying an additional 233 shares during the period. Balyasny Asset Management LLC purchased a new stake in shares of OptimizeRx in the third quarter valued at approximately $433,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of OptimizeRx by 89.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 86,369 shares of the company’s stock valued at $7,389,000 after purchasing an additional 40,783 shares in the last quarter. Institutional investors own 86.12% of the company’s stock.

About OptimizeRx

OptimizeRx Corp. is digital health company, which engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging; and brand support.

See Also: How to calculate the annual rate of depreciation

Get a free copy of the Zacks research report on OptimizeRx (OPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.